Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,012,136)	$ (2,195,156)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	702,236	820,792
Bad debt expense	923,559	903,710
Share based compensation	286,310	223,345
Issuance of stock for compensation		336,000
Change in fair value of contingent consideration		(48,035)
Loss on disposal of property and equipment		6,197
Non cash interest expense	76,475	105,459
Gain on settlement of contingent consideration		(1,969,245)
Change in assets and liabilities
Accounts receivable	530,634	(4,113,466)
Inventories	(196,555)	922,503
Prepaid expenses and other current assets	(493,843)	114,171
Accounts payable and accrued liabilities	(69,192)	3,025,709
Deferred revenue	(94,249)	(178,553)
Net cash used in operating activities	(346,761)	(2,046,569)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(56,592)	(171,196)
Cash paid for acquisition of PhotoMedex, Inc.		(5,000,000)
Net cash used in investing activities	(56,592)	(5,171,196)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of DermaWand® asset purchase agreement	(225,000)	(150,000)
Proceeds from issuance of common stock, net of offering costs		6,982,930
Proceeds from exercise of options		55,559
Proceeds from note payable from related party	100,000
Repayments of long-term debt to related party	(507,809)	(87,441)
Payments of deferred consideration for asset acquisition	(160,414)	(14,583)
Proceeds from issuance of preferred stock	403,200
Proceeds from long-term debt to related party		2,000,000
Settlement payment made for PhotoMedex Acquisition		(2,000,000)
Net cash (used in) provided by financing activities	(255,031)	6,786,465
Effect of exchange rates on cash and cash equivalents	(17,279)	1,683
NET DECREASE IN CASH AND CASH EQUIVALENTS	(675,663)	(429,617)
CASH AND CASH EQUIVALENTS, beginning of the period	1,258,360	1,390,641
CASH AND CASH EQUIVALENTS, end of the period	582,697	961,024
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Taxes paid
Interest paid	394,797
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITY:
Cashless exercise of options		43
Conversion of accounts payable to note payable	298,716
PhotoMedex [Member]
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITY:
Fair value of assets acquired		9,198,043
Fair value of deferred consideration		(4,198,043)
Cash paid for acquisition		5,000,000
Contingent consideration owed to PhotoMedex		3,579,760
Other receivables amount forgiven		(837,708)
Payables extinguished		1,017,193
Settlement payment made		(2,000,000)
Assignment of deposit amount		210,000
Gain on settlement of contingent consideration		1,969,245
Ermis Labs [Member]
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITY:
Fair value of assets acquired		1,981,822
Fair value of deferred consideration		(1,131,822)
Cash paid for acquisition
Issuance of common stock		(850,000)
Amazon [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from note payable from related party	145,000
Repayments of note payable to Amazon	$ (10,008)